The focus of vaccination at this stage is to close the gap in immunization levels for different target groups and further reduce the risk of severe disease and death. For people aged 3-17 who have been infected and have not completed basic immunization, the vaccines used for vaccination shall be implemented in accordance with the relevant requirements in the previous period.

The recombinant new coronavirus 4-valent S trimer protein vaccine has been included in emergency use and can be used for booster immunization for people over 18 years.